Download Raph-O-Presentation-210415

Systemic Anti Cancer Therapy
(SACT)
Cancer 52
Ralphael Oghagbon
What is currently available
and how do I gain access?
Coverage Map
Nationally
Numbers in Treatment
Top Regimens
Area Team
Data Completeness
Benchmarking
Post Chemo Mortality
Hospital
Data Completeness
Top Regimens
www.chemodataset.nhs.uk
Coverage Map: A National
Perspective
So… what do the numbers tell us?
February 14 to
January ‘15
March 14 to
February 15
Patients Receiving Drug
Treatments
Regimens Commenced
163,840
165,256
278,354
282,646
Cycles Commenced
774,958
790,868
The figures listed above represent the number of patients reported to the CIU
through SACT, for whom treatment activity has been submitted for the period
covering August 2013 through July 2014 inclusive.
How good is the data nationally?
SACT data completeness, March 2014 to February 2015
Key

Increase in completeness since comparison period

Decrease in completeness since comparison period

No change in completeness since comparison period

100% completion (for non-mandatory items)
M
Mandatory item (always 100%)
How do less common cancers
compare to other diagnostic
groups
Can I find out how complete my
hospital’s Rare Cancer data is?
Top Regimens by Diagnostic
Group
Brain/CNS
ICD10: C47, C69-C72
All submitting trusts aggregated
Data received for October 2013 - September
2014. Patients aged 16 and over
These reports are available at a provider
level
There are in excess of 109 regimens for
this disease group
Top Regimens by Diagnostic
Group
Sarcoma
ICD10: C40-C41, C46, C49 or various
morphology codes
All submitting trusts aggregated
Data received for October 2013 - September
2014. Patients aged 16 and over
These reports are available at a provider
level
There are in excess of 165 regimens for
this disease group
Top regimens reported for gastro-intestinal stromal
tumours
Morphology: M8936
All submitting trusts aggregated
Data received for October 2013 - September 2014. Patients aged 16 and over
Top Regimens
IMATINIB
SUNITINIB
REGORAFENIB
TRIAL
CHOP R
DASATINIB
<regimen(s) not recognised>
CP-CCR3559 BI 836845 DOSE EXP WEEKLY SCH
CP-CCR3941-ONX-0801 WEEKLY SCHEDULE
SA-CCR3877-IMAT+BKM120-COMBINATION
Total patients
Total patients by Intent of Treatment
Curative* Palliative Not recorded Total
32 (16%) 37 (18%)
133 (66%)
202
19 (56%)
15 (44%)
34
1 (3%) 13 (45%)
15 (52%)
29
1 (10%)
9 (90%)
10
1 (100%)
1
1 (100%)
1
7 (100%)
7
2 (100%)
2
1 (100%)
1
4 (100%)
4
33 (12%) 71 (25%)
180 (63%)
284
*Curative group includes adjuvant and neo-adjuvant intent
Post Chemotherapy Mortality Analysis
 From 25th July 2014 all NHS providers of chemotherapy in England have
been able to access their 30/60/90-day post chemotherapy mortality analysis
through the secure online portal.
 This analysis is available by tumour group and will provide a national
comparison.
 It is essential that clinical teams within provider organisations check the
accuracy of their data and contact the team in Oxford where there are any
possible discrepancies.
 A letter to Medical Directors and Lead Chemotherapy Consultants has been
sent out raising awareness of these reports.
Post Chemotherapy Mortality Analysis
(2)
For demonstration purposes only
Post Chemotherapy Survival Analysis
Less Common Cancer all treatment intents
For demonstration purposes only
Cancer Drugs Fund (CDF) data
• NHS England is responsible for delivery of the Cancer Drugs Fund
• Public Health England commissioned to audit Cancer Drugs Fund
• Expectation for Cancer Drugs Fund treatments to be reported through
SACT by each hospital
Improving Stakeholder
Engagement
Members of the CIU team will be attending the following meetings:
• NHS England Area Team Pharmacist Meeting
• NHS England Chemotherapy Clinical Reference Group
• Chemotherapy Clinical Information Group
• NCIN Site Specific Clinical Reference Groups (SSCRG)
e.g. CNS workshop, CTYA meeting
Would you like to know more about SACT? Please contact the team,
we are always happy to discuss the project or meet with you.
E-mail: [email protected]